Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMB-1018972 in Angina Due to Obstructive Coronary Artery Disease
NCT04826172Phase 2Completed
- Sponsor
- Imbria Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ninerafaxstat in angina pectoris, coronary artery disease (CAD), sponsored by Imbria Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
ninerafaxstat
03
Conditions
angina pectoriscoronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04826172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826172.